The company had applied in response to a call for COVID-19 home tests accessible to people with disabilities (https://www.poctrn.org/web/radx-accessible-tests/) with a project based on our emerging saliva testing platform.
“We are excited to receive this approval as this project closely aligns with our vision for easy to use, saliva based testing for Covid-19, other infectious diseases, and biomarker monitoring. The RADx program has a history of supporting impactful, cutting-edge diagnostics and we are honored to be part of that program. I am immensely proud of our team for putting together a compelling proposal and working closely with NIH staff to refine the concept.” says Marco Witteveen, CEO AegirBio
This disclosure contains information that AegirBio is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 17-07-2023 20:32 CET.
AegirBio is a Swedish diagnostics company founded in 2019 to offer tests to monitor and optimize the dosage of biological drugs via its unique patented technology platform. In June 2020, AegirBio was listed on the Nasdaq First North Growth Market. The company's ambition is, in addition to bringing innovative diagnostic technology to the market, to make diagnostics more accessible, easier to use and to provide accurate and easily transferable results. For more information, see Aegirbio's website www.aegirbio.com
The company's Certified Adviser is Eminova Fondkomission AB | 08-684 211 00 | firstname.lastname@example.org